Skip to main content
. 2016 May 31;113(24):E3441–E3450. doi: 10.1073/pnas.1602070113

Fig. S6.

Fig. S6.

(A) The TLR4 antagonist (+)-naloxone (blue hatch; 7 d) was administered 5 wk after morphine (5 d, administered 10 d after CCI; shaded area), and absolute thresholds for mechanical allodynia were quantified in SD rats. (B) The P2X7R antagonist A438079 (purple hatch; 7 d) was administered 5 wk after morphine (5 d, administered 10 d after CCI; shaded area), and absolute thresholds for mechanical allodynia were quantified in SD rats. (C and D) The P2X7R antagonist Brilliant Blue G (purple hatch; 7 d) was administered 5 wk after morphine (5 d, administered 10 d after CCI; shaded area) and absolute thresholds for mechanical allodynia quantified in F344 (C) and SD rats (D). (E) The caspase-1 inhibitor ac-YVAD-cmk (green hatch; 5 d) was administered 5 wk after morphine (5 d, administered 10 d after CCI; shaded area), and absolute thresholds for mechanical allodynia were quantified in SD rats. (F–H) Respective levels of phospho-NR1, GRK2, GLT-1, P2X7R, phospho-p38/total p38 ratio, NF-κB (p65 subunit), NLRP3, procaspase-1, and caspase-1 were quantified after treatment with (+)-naloxone (F), A438079 (G), or ac-YVAD-cmk (H). Representative blots are presented. *P < 0.05; **P < 0.01; ***P < 0.001 (inhibitor vs. control). Data are presented as mean ± SEM; n = 6 or 7 per group.